4.8 Article

Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 125, Issue 5, Pages 2069-2076

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI80554

Keywords

-

Funding

  1. Angelman Syndrome Foundation (ASF)
  2. Simons Foundation (SFARI) [275234]
  3. Netherlands Organization for Scientific Research (NWO-ZoN-MW)
  4. Dutch (Prader-Willi/Angelman Vereniging [PWAV])
  5. Italian (Organizzazione Sindrome di Angelman [OR.S.A.])
  6. French (Association Francaise du syndrome d'Angelman [AFSA]) Angelman parent organizations
  7. Fundacao para a Ciencia e Tecnologia and Fundacao Amelia de Mello
  8. Nina Foundation

Ask authors/readers for more resources

Angelman syndrome (AS) is a severe neurodevelopmental disorder that results from loss of function of the maternal ubiquitin protein ligase E3A (UBE3A) allele. Due to neuron-specific imprinting, the paternal UBE3A copy is silenced. Previous studies in murine models have demonstrated that strategies to activate the paternal Ube3a allele are feasible; however, a recent study showed that pharmacological Ube3a gene reactivation in adulthood failed to rescue the majority of neurocognitive phenotypes in a murine AS model. Here, we performed a systematic study to investigate the possibility that neurocognitive rescue can be achieved by reinstating Ube3a during earlier neurodevelopmental windows. We developed an AS model that allows for temporally controlled Cre-dependent induction of the maternal Ube3a allele and determined that there are distinct neurodevelopmental windows during which Ube3a restoration can rescue AS-relevant phenotypes. Motor deficits were rescued by Ube3a reinstatement in adolescent mice, whereas anxiety, repetitive behavior, and epilepsy were only rescued when Ube3a was reinstated during early development. In contrast, hippocampal synaptic plasticity could be restored at any age. Together, these findings suggest that Ube3a reinstatement early in development may be necessary to prevent or rescue most AS-associated phenotypes and should be considered in future clinical trial design.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available